Viatris to acquire Oyster Point and Famy Life Sciences
Pharmaceutical Technology
NOVEMBER 8, 2022
Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.
59 
Let's personalize your content